A chronic neuroinflammatory event mediated by persistent microglia activation has been well recognized as a major pathophysiological contributor to the progression of neurodegenerative processes in Parkinson's disease (PD). Identification of key targets contributing to sustained microglia activation and the regulation of these targets could provide potential treatments to halt disease progression. In this study, we show that microglial Kv1.3, a voltage‐gated potassium channel, was highly upregulated in aggregated α‐synuclein (αSyn)‐stimulated primary microglia cultures, animal models of PD, as well as in human PD postmortem samples. Importantly, patch‐clamp electrophysiological studies confirm that the observed Kv1.3 upregulation translates to increased Kv1.3 channel activity. We further demonstrate that Fyn, a non‐receptor tyrosine kinase, modulated the transcriptional upregulation of microglial Kv1.3. Using multiple state‐of‐the‐art techniques, including DuoLink PLA technology, we show that Fyn directly binds to Kv1.3 and post‐translationally modified its channel activity. Furthermore, we demonstrate the functional relevance of Kv1.3 with respect to neuroinflammation by using Kv1.3 knockout (KO) microglia and the Kv1.3‐specific pharmacological inhibitor PAP‐1. Kv1.3 KO microglial cells treated with aggregated αSyn produced fewer pro‐inflammatory cytokines. PAP‐1 significantly attenuated aggregated αSyn‐induced inflammation in both a microglial cell line and primary microglia, thus highlighting Kv1.3's importance in inflammation. Oral administration of PAP‐1 significantly inhibited MPTP‐induced neurodegeneration and inflammation in vivo. PAP‐1 also significantly reversed behavioral deficits and dopamine loss in MitoPark mice, a progressive model of PD. Our results collectively show that the Fyn‐dependent Kv1.3 channel plays an important role in inflammation in PD and has potential therapeutic implications. Support or Funding Information ES026892, NS088206, NS100090, Llyod Chair This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Hydrogen sulfide (H2S), the gas with the odor of rotten eggs, was formally discovered in 1777, over 239 years ago. For many years, it was considered an environmental pollutant and a health concern only in occupational settings. Recently, however, it was discovered that H2S is produced endogenously and plays critical physiological roles as a gasotransmitter. Although at low physiological concentrations it is physiologically beneficial, exposure to high concentrations of H2S is known to cause brain damage, leading to neurodegeneration and long-term neurological sequelae or death. Neurological sequelae include motor, behavioral, and cognitive deficits, which are incapacitating. Currently, there are concerns about accidental or malicious acute mass civilian exposure to H2S. There is a major unmet need for an ideal neuroprotective treatment, for use in the field, in the event of mass civilian exposure to high H2S concentrations. This review focuses on the neuropathology of high acute H2S exposure, knowledge gaps, and the challenges associated with development of effective neuroprotective therapy to counteract H2S-induced neurodegeneration.
Hydrogen sulfide (H S) is a highly neurotoxic gas. It is the second most common cause of gas-induced deaths. Beyond mortality, surviving victims of acute exposure may suffer long-term neurological sequelae. There is a need to develop countermeasures against H S poisoning. However, no translational animal model of H S-induced neurological sequelae exists. Here, we describe a novel mouse model of H S-induced neurotoxicity for translational research. In paradigm I, C57/BL6 mice were exposed to 765 ppm H S for 40 min on day 1, followed by 15-min daily exposures for periods ranging from 1 to 6 days. In paradigm II, mice were exposed once to 1000 ppm H S for 60 minutes. Mice were assessed for behavioral, neurochemical, biochemical, and histopathological changes. H S intoxication caused seizures, dyspnea, respiratory depression, knockdowns, and death. H S-exposed mice showed significant impairment in locomotor and coordinated motor movement activity compared with controls. Histopathology revealed neurodegenerative lesions in the collicular, thalamic, and cortical brain regions. H S significantly increased dopamine and serotonin concentration in several brain regions and caused time-dependent decreases in GABA and glutamate concentrations. Furthermore, H S significantly suppressed cytochrome c oxidase activity and caused significant loss in body weight. Overall, male mice were more sensitive than females. This novel translational mouse model of H S-induced neurotoxicity is reliable, reproducible, and recapitulates acute H S poisoning in humans.
Aims The pathology of Alzheimers's disease (AD) is characterized by the presence of amyloid plaques (APs), neurofibrillary tangles (NFTs), degenerating neurons, and an abundance of reactive astrocytes and microglia. We aim to examine the association between glia maturation factor (GMF) expression, activated astrocytes/microglia, APs, and NFTs in AD affected brain regions. Methods Brain sections were stained with Thioflavin-S to study AD pathology and sequentially immunolabeled with antibodies against GMF, glial fibrillary acidic protein (GFAP, marker for reactive astrocytes), and Ionized calcium binding adaptor molecule 1 (Iba1, marker for activated microglia) followed by visualization with avidin-biotin peroxidase complex. Results Our double immunofluorescence labeling with cell-specific markers demonstrated the glial localization of GMF. The immunohistochemical data showed that APs and NFTs are associated with increased expression of GMF in reactive glia of AD brains compared to non-AD controls. Conclusions This is the first report that shows GMF, a mediator of CNS inflammation, is expressed in the brain regions affected in AD and that GMF is mainly localized in reactive astrocytes surrounding APs/NFTs. The distribution of GMF-immunoreactive cells in and around Thioflavin-S stained APs and NFTs suggests involvement of GMF in inflammatory responses through reactive glia and a role of GMF in AD pathology.
Hydrogen sulfide (H2S) is a colorless, highly neurotoxic gas. It is not only an occupational and environmental hazard but also of concern to the Department of Homeland Security for potential nefarious use. Acute high-dose H2S exposure causes death, while survivors may develop neurological sequelae. Currently, there is no suitable antidote for treatment of acute H2S-induced neurotoxicity. Midazolam (MDZ), an anti-convulsant drug recommended for treatment of nerve agent intoxications, could also be of value in treating acute H2S intoxication. In this study, we tested the hypothesis that MDZ is effective in preventing/treating acute H2S-induced neurotoxicity. This proof-of-concept study had two objectives: to determine whether MDZ prevents/reduces H2S-induced mortality and to test whether MDZ prevents H2S-induced neurological sequelae. MDZ (4 mg/kg) was administered IM in mice, 5 min pre-exposure to a high concentration of H2S at 1000 ppm or 12 min post-exposure to 1000 ppm H2S followed by 30 min of continuous exposure. A separate experiment tested whether MDZ pre-treatment prevented neurological sequelae. Endpoints monitored included assessment of clinical signs, mortality, behavioral changes, and brain histopathological changes. MDZ significantly reduced H2S-induced lethality, seizures, knockdown, and behavioral deficits (p < 0.01). MDZ also significantly prevented H2S-induced neurological sequelae, including weight loss, behavior deficits, neuroinflammation, and histopathologic lesions (p < 0.01). Overall, our findings show that MDZ is a promising drug for reducing H2S-induced acute mortality, neurotoxicity, and neurological sequelae.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.